• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > GlaxoSmithKline > January 25, 2011

      GlaxoSmithKline Starts 2 Phase III Studies In Advanced/Metastatic Melanoma

      Posted Atonline.wsj.com

      LONDON (Dow Jones)--GlaxoSmithKline (GSK.LN), the drug giant, Monday announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation.

      MAIN FACTS:

      The studies will separately assess the efficacy and safety of two investigational agents, GSK2118436 and GSK1120212, to determine their individual ability to stop or slow the progression of skin cancer in patients whose tumours contain a BRAF V600 mutation, which occurs in 50 to 60 percent of melanoma patients.

      Commencement of these studies confirms previously announced plans to progress these assets into Phase III.

      Shares at 1305 GMT up 1.34% at 1171.50 pence valuing the company at GBP60.87 billion.

      Jan 25, 2011


       

      Share this Article!

    Back to top^